profit from every $100 of sales.
$0$100
Immunovant
$37.04+3.72% today
+61.8% in 1 year
1-year low $22.021-year high $44.96
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Immunovant sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2026, with -$506 million of profit last year.
SalesProfit
Immunovant vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Immunovant | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Immunovant's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -208 | -270 | -438 | -533 | |
| -208 | -270 | -438 | -532 | |
| -211 | -259 | -414 | -506 | |
| -1.71 | -1.88 | -2.73 | -2.77 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 406 | 666 | 776 | 957 |
| Cash | 377 | 635 | 714 | 902 |
| Total debt | 1 | 0 | 0 | 0 |
| Total liabilities | 43 | 49 | 69 | 104 |
| 362 | 618 | 707 | 853 | |
| 123 | 138 | 152 | 182 | |
| -45.2% | -34.5% | -48.9% | -49.4% | |
| -58.2% | -42.0% | -58.5% | -59.3% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -188 | -214 | -376 | -407 | |
| 0 | 0 | 1 | 0 | |
| -188 | -215 | -377 | -407 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 32 | 41 | 49 | 56 |
Valuation
- –
- –
- –
- 8.0×
- –
- –
- –
- -5.3%
- -6.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -62.5%
- -50.2%
- -68.2%
- -52.8%
- -62.5%
- –
Growth
- –
- –
- −8.1%
- –
- +13.6%
Financial health
- 1.7×
- 0.00
- 0.0%
- –
- 9.09
- 9.09
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 958
Bottom 21%of 888
Bottom 17%of 987
What analysts expect
- Average price target
- $45.50
- Range
- $41.00 – $50.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 6, 2026 | -0.61 | -0.72 | +15.3% |
| Nov 10, 2025 | -0.73 | -0.72 | −1.4% |
| Aug 11, 2025 | -0.60 | -0.69 | +13.0% |
| May 29, 2025 | -0.64 | -0.71 | +10.3% |
| Feb 6, 2025 | -0.76 | -0.73 | −4.1% |
| Nov 7, 2024 | -0.74 | -0.60 | −23.3% |
| Aug 6, 2024 | -0.60 | -0.53 | −13.2% |
| May 29, 2024 | -0.52 | -0.43 | −20.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
19No pass
Benjamin Graham
40No pass
Philip Fisher
30No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
21No pass
Questions about Immunovant
Is Immunovant a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Immunovant AI analysis
What does Immunovant do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is in Biotechnology, based in Durham, NC, United States, with 315 employees.
Does Immunovant pay a dividend?
No. Immunovant does not pay a dividend at the moment.
Is Immunovant stock halal?
Yes. Immunovant passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Immunovant stock done over the past year?
Up 61.8% over the past twelve months, to $37.04. It traded between $22.02 and $44.96 and is 17.6% below its high.
Who are Immunovant's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Immunovant's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.